Program
PA032
A development code. Also written as “Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug)”.
Its studies are led by Hangzhou Yirui Pharmaceutical Technology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hangzhou Yirui Pharmaceutical Technology | 33 open or running | phase 1since Nov 20, 2025 | Nov 20, 2025 | Sep 30, 2027phase 1 · NCT07285967 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 20, 2025First study: phase 1 study in SafetyFirst studyNCT07285967 · 64 planned
- Jun 22, 2026Phase 1 study in Health Adult SubjectsNCT07673458 · 18 planned · China
- Oct 9, 2026Phase 1 study in SafetyNCT07878481 · 64 planned
Ahead
- Sep 30, 2027Primary completion: phase 1 study in SafetyNCT07285967
- Oct 30, 2027Primary completion: phase 1 study in SafetyNCT07878481
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07878481Safety | 1 | Not yet recruiting | Oct 30, 2027 | 64 |
| NCT07673458Health Adult Subjects · China | 1 | Recruiting | Sep 18, 2026 | 18 |
| NCT07285967Safety | 1 | Not yet recruiting | Sep 30, 2027 | 64 |
How it is read
Names in the registry
- “Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug)”, 2 entries
- “PA032”, 1 entry
Codes read as this program: PA032.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.